Combined inhibition of MDM2 and PARP lead to a synergistic anti-tumoral response in p53 wild-type rhabdomyosarcoma models
Guillem Pons, Patricia Zarzosa, Gabriel Gallo-Oller…·Josep M Roma
This study shows that combining MDM2 and PARP inhibitors synergistically inhibits p53 wild-type rhabdomyosarcoma growth in vitro and in vivo.